ºù«ÍÞÊÓƵ

Public policy has the potential to enable the development of the next generation of medical advances and unlock the power of health. ºù«ÍÞÊÓƵ's role in these discussions is to work to ensure that policy positively impacts the people who rely on our work, our employees and our ability to continue to develop new products. At the federal and state levels, we engage with governments, think tanks, trade associations, patient groups and other organizations to find policy solutions to the complex issues that challenge our healthcare system. It is our responsibility to help policymakers understand ºù«ÍÞÊÓƵ's viewpoints on major healthcare issues.

ºù«ÍÞÊÓƵ's public policy engagement is guided by the following principles:

• ºù«ÍÞÊÓƵ is committed to ethical behavior and transparency and is guided by our Code of Business Conduct in all our activities, including public policy engagement. ºù«ÍÞÊÓƵ's public policy activities comply with all applicable laws and regulations and adhere to ºù«ÍÞÊÓƵ policies. ºù«ÍÞÊÓƵ, relevant ºù«ÍÞÊÓƵ employees, and external lobbyists and firms register as lobbyists and file lobbying and contribution disclosures as required by applicable law.
• The Government Affairs function has the primary responsibility for public policy engagement in the U.S. under the direction of the Vice President of Government Affairs. The Public Policy Committee of the Board of Directors reviews an annual report of ºù«ÍÞÊÓƵ's public policy activities, including advocacy priorities, political contributions, lobbying activities, and trade association memberships and dues.
• ºù«ÍÞÊÓƵ pursues activities to shape policies that impact the Company and benefit the people who need our products, with a focus on improving access to new medical advances, and helping people live fuller, healthier lives.

ºù«ÍÞÊÓƵ's Government Affairs function, under the direction of the Vice President, Government Affairs, is responsible for our U.S. advocacy activities, including managing all direct advocacy at the federal, state, and local levels, and managing ºù«ÍÞÊÓƵ's relationships with trade associations and similar groups with respect to their advocacy efforts. Our Federal Government Affairs office in Washington, D.C. is responsible for advocacy activities with the U.S. Congress and the federal government. Advocacy at the U.S. state level is managed by our State Government Affairs function. ºù«ÍÞÊÓƵ also hires outside firms that can provide expertise on our key policy issues. ºù«ÍÞÊÓƵ does not currently make direct expenditures towards U.S. federal or state grassroots lobbying communications to the general public. Were ºù«ÍÞÊÓƵ to engage in this area, such activity would be managed by the Vice President of Government Affairs.

The Public Policy Committee of the ºù«ÍÞÊÓƵ Board of Directors is responsible for oversight of ºù«ÍÞÊÓƵ's Government Affairs function and public policy issues that affect or could affect ºù«ÍÞÊÓƵ's business, performance, and public image, as well as reviewing and evaluating ºù«ÍÞÊÓƵ's governmental affairs and political participation, including advocacy priorities, political contributions, lobbying activities, and trade association memberships. The Public Policy Committee also has responsibility for evaluating ºù«ÍÞÊÓƵ's sustainability and social responsibility practices and reviewing social, political, economic, and environmental trends. For additional information regarding ºù«ÍÞÊÓƵ's Public Policy Committee, please refer to the Committee's charter.

ºù«ÍÞÊÓƵ is committed to enabling people to live fuller, healthier lives through better health and we strive to make an impact on policies and priorities that have a positive effect on people's health and well-being, including enabling broader accessibility to and affordability of medical innovation. In furtherance of this commitment, ºù«ÍÞÊÓƵ engages in advocacy with respect to public policy developments that may have a significant impact on this objective and on its business. ºù«ÍÞÊÓƵ regularly engages in advocacy on the following issues: promoting access to medical innovation; promoting competitive tax policy that enhances innovation; global trade issues; strengthening our supply chain; and promoting sustainability and responsible stewardship of our resources.

ºù«ÍÞÊÓƵ files quarterly reports, in compliance with the Lobbying Disclosure Act, that include: 1) total federal lobbying expenditures, 2) the name of the specific piece of legislation or subject that was the topic of communication, 3) disclosure of ºù«ÍÞÊÓƵ individuals who lobbied on behalf of ºù«ÍÞÊÓƵ and 4) identification of the legislative body or executive branch that was contacted. The quarterly reports provide additional detail on active lobbying priorities and incorporate expenses associated with lobbying the federal government, including our Federal Government Affairs office and the portion of trade association dues associated with federal lobbying. In 2023, ºù«ÍÞÊÓƵ reported $3,890,000 in U.S. federal lobbying. ºù«ÍÞÊÓƵ's latest Federal lobbying disclosure filings can be found on the Ìýor theÌýÌý The Public Policy Committee of the ºù«ÍÞÊÓƵ Board of Directors reviews an annual report of our advocacy priorities.

Download ºù«ÍÞÊÓƵ's most recent LD-2 here. Please see below to download previous quarters' reports of ºù«ÍÞÊÓƵ's LD-2.

ºù«ÍÞÊÓƵ is a member of U.S. trade organizations that engage in lobbying and other political activity to champion and protect the interests of ºù«ÍÞÊÓƵ, our industry and, most importantly, the people who rely on our products to achieve good health. Each year, the Government Affairs function, under the direction of the Vice President, Government Affairs, assesses our participation in trade associations and other tax-exempt organizations that write and endorse model legislation. These industry and trade groups and similar organizations generally represent the healthcare community and the broader business community. Collaboration and cooperation with a wide array of people and organizations are critical to meet the needs of patients today. We strive to align with organizations whose overall advocacy platform demonstrates values that mirror our own. An organization's membership and robust governance process collectively drives the development of individual positions. We pride ourselves on taking an active role in the trade associations we have joined, expressing our opinions and making the case for the position we believe will produce the most appropriate policy outcomes. ºù«ÍÞÊÓƵ's participation as a member of these various industry and trade groups comes with the understanding that we may not always agree with the positions of the larger organization and/or other members. We raise our concerns, as needed and as appropriate, on issues that we believe are important to us and our stakeholders.

The Public Policy Committee of the ºù«ÍÞÊÓƵ Board of Directors reviews an annual report of our major trade association memberships, the amount of dues and the amount used for lobbying.

Below is a list of U.S. trade associations to which ºù«ÍÞÊÓƵ paid dues of $50,000 or more in 2024, and which lobby in the U.S. at the federal level. Also provided for each trade association is the percentage of the 2024 dues they collect from member companies utilized by that organization for federal lobbying.

• Advanced Medical Technology Association (14%)
• American Clinical Laboratory Association (22%)
• BIOCOM San Diego (10%)
• Business Roundtable (24%)
• Columbus Partnership (8%)
• Consumer Brands Association (14%)
• Council for Responsible Nutrition (15%)
• Healthcare Nutrition Council (5%)
• Infant Nutrition Council of America (25%)
• International Dairy Food Association (16%)
• Medical Device Manufacturers Association (30%)
• National Association of Manufacturers (22%)
• U.S. Asean Business Council (1%)
• U.S. Chamber of Commerce (40%)

To download previous years' trade association membership reports, please see below.